PSTI stock forecast
Our latest prediction for Pluristem Therapeutics, Inc.'s stock price was made on the Sept. 30, 2020 when the stock price was at 10.53$.
In the short term (2weeks), PSTI's stock price should underperform the market by -0.58%. During that period the price should oscillate between -10.34% and +13.70%.
In the medium term (3months), PSTI's stock price should underperform the market by -9.61%. During that period the price should oscillate between -43.12% and +29.86%.Get email alerts
Create a solid portfolio with PSTI
About Pluristem Therapeutics, Inc.
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.60$ per share.
The book value per share is 0.25$
Three months stock forecastSept. 30, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|